Fall 2017 Newsletter

Follow our latest updates in our Newsletters and Annual Reports

Fall 2017 Newsletter
7th Residency Announcement

Exciting Residency Announcement!

ACGME approves seventh resident complement; first increase in over 30 years!

Grand Rounds

Grand Rounds and Case Studies

Check out our weekly presentations



USC Ophthalmology Researchers Find More
Effective Treatments For Blinding Eye Diseases


Case Study: Donut in a Grown-up

Rayess Berry
Presenter: Nadim Rayess, MD Discussant: Jesse L. Berry, MD


  • 45-year-old male presented with decreased peripheral vision of two-year duration
  • Denied flashing lights, floaters or curtains

Exam Findings

  • VAcc: 20/20; 20/20
  • Pupils: RR OU, no RAPD
  • IOP: 14; 15
  • EOM: Full OU
Figure 1
Figure 1: Fundus photograph of the right eye (left panel) showing pigmented dark brown/black lesion covering the disc and appears to be extending to the peripapillary retina with fibrillating margins. Fundus photography of the left eye (right panel) is normal except for mild peripapillary atrophy temporal to the optic disc.


Figure 2
Figure 2: (A) B-scan showing an elevated hyperechoic lesion overlying the optic nerve measuring 1.57mm (height) by 3.76mm (width). (B) A-scan demonstrates that the lesion is of high internal reflectivity.


Differential Diagnosis

  • Melanocytoma
  • Juxtapapillary choroidal melanoma
  • Choroidal nevus
  • Hyperplasia of the RPE
  • Combined hamartoma of the retina and RPE
  • Adenoma of RPE
  • Metastatic melanoma

Additional Investigations

  • Fluorescein angiogram was performed to further characterize the lesion (Figure 3)
  • Humphrey visual field (HVF 30-2) was also obtained (Figure 4) as the patient reported decreasing peripheral vision. In addition, visual field changes have been reported with the most common visual field defect being an enlarged blind spot in approximately 75 to 90 percent of patients with melanocytoma.

Figure 3
Figure 3: Fluorescein angiography of the right eye, early phase (left panel) demonstrates hypofluorescence in the location of the hyperpigmented lesion that persisted on the late phase (right panel).

Figure 4
Figure 4: HVF 30-2 of the right eye (left panel) demonstrates diffusely diminished peripheral visual field with only a small central field maintained. In contrast, the left eye (right panel) represents a normal visual field.



  • Melanocytoma


  • Melanocytoma (magnocellular nevus) is a benign tumor considered to be a variant of a melanocytic nevus
  • The pathogenesis is unknown but it is thought to be either an acquired lesion or a congenital lesion that may start off amelanotic and acquire dense pigmentation with age


  • The patient was followed up with yearly dilated fundus examination with ancillary fundus photography and B-scan ultrasonography to document the dimensions of the lesion.
  • There are no treatments available to prevent growth of a melanocytoma. Patients are examined at least yearly to ensure there is no growth. More frequent examinations are warranted if there is documented growth with suspicion for possible transformation into a malignant melanoma.
Figure 5
Figure 5: Fundus photography of the melanocytoma in 2014 (left panel) and 2016 (right panel) showing a similar appearance in the size, borders and pigmentation of the lesion.


Prognosis and Future Directions

  • Majority of melanocytomas do not grow or cause visual symptoms. However, a mild decrease in visual acuity can occur in around 26 percent of patients secondary to retinal exudation, subretinal fluid or optic disc edema.
  • Severe vision loss is extremely rare, but may occur secondary to a central retinal vein occlusion, tumor necrosis or malignant transformation.
  • 10 to 15 percent of melanocytomas grow over years. An initial thickness ≥ 1.5mm predicts future growth.
  • Malignant transformation can occur in 1 to 2 percent of cases. Patients typically present with a progressively growing lesion that is associated with decreasing visual acuity.
  • Other etiologies for a growing melanocytoma include a complication of tumor necrosis that occurs when the melanocytoma outgrows its vascular supply. In addition, a juxtapapillary melanoma needs to be considered in a growing lesion.
  • MRI can be helpful in determining extent of retrolaminar extension of the lesion especially when suspecting transformation to choroidal melanoma and also aid in the diagnosis of complications of melanocytoma such as tumor necrosis.


  • Shields JA, Demirci H, Mashayekhi A, Eagle RC, Shields CL. Melanocytoma of the optic disk: A review. Surv Ophthalmol. 2006 Mar-Apr;51(2):93-104.
  • Osher RH, Shields JA, Layman PR. Pupillary and visual field evaluation in patients with melanocytoma of the optic disc. Arch Ophthalmol. 1979;97:1096-1099.
  • Singh AD, Platt SM, Lystad L, et al. Optic Nerve Assessment Using 7-Tesla Magnetic Resonance Imaging. Ocul Oncol Pathol. 2016 Apr;2(3):178-180.
  • Meyer D, Ge J, Blinder KJ, Sinard J, Xu S. Malignant transformation of an optic disk melanocytoma. Am J Ophthalmol. 1999;127(6):710-714.
  • Baartman BJ, Ahmad B, Srivastava S, Jones S, Singh AD. MELANOCYTOMA OR JUXTAPAPILLARY MELANOMA? Retin Cases Brief Rep. 2017 Jan 2.
  • Filloy A, Arias L, Ascaso FJ, Caminal JM. Swept source optical coherence tomography imaging of optic disc melanocytoma. Clin Exp Ophthalmol. 2016 Oct 11.


Section Editors


Produced by: Monica Chavez, John Daniel, Joseph Yim and Dr. Vivek Patel
Scroll Up To Top

USC Roski Eye Institute

1450 San Pablo St., 4th Floor,
Los Angeles, CA 90033

USC Roski Eye Institute

65 N. First Ave., Suite 101,
Arcadia, CA 91006

USC Roski Eye Institute

625 S. Fair Oaks Ave., Suite 400,
Pasadena, CA 91105

USC Roski Eye Institute
USC Village

835 W. Jefferson Blvd., Suite 1720
Los Angeles, CA 90089

Children’s Hospital
Los Angeles

4650 Sunset Blvd.,
Los Angeles, CA 90027

View Full Desktop Version

Coronavirus (COVID-19) Announcement

Due to ongoing developments with COVID-19, we are only able to see patients with urgent eye problems at this time. If you have any questions or concerns, please call us at 323-442-6335.